A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Lademirsen (Primary)
- Indications Hereditary nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Regulus Therapeutics
- 16 Nov 2018 Planned End Date changed from 1 Sep 2019 to 1 Mar 2019.
- 16 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
- 06 Jul 2018 Status changed from recruiting to active, no longer recruiting.